|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/01 | |
| A61K 38/03 | |||
| A61K 38/04 | |||
| A61P 9/00 | |||
| A61P 11/00 | |||
| A61P 17/00 | |||
| A61P 25/00 | |||
| A61P 31/12 | |||
| A61P 37/00 |
| (11) | Patento numeris | 2650007 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13002792.3 |
| Europos patento paraiškos padavimo data | 2009-06-02 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-10-16 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2015-05-20 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| PCT/EP2008/0043 | 2008-05-30 | WO |
| (72) |
Bonny, Christophe, CH
|
| (73) |
Xigen Inflammation Ltd.,
Arch. Makariou III 195 Neocleous House, 3030 Limassol,
CY
|
| (54) | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various autoimmune diseases |
| Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various autoimmune diseases |